660 results on '"Sinico, Renato Alberto"'
Search Results
2. Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis
- Author
-
Gatto, Mariele, Frontini, Giulia, Calatroni, Marta, Reggiani, Francesco, Depascale, Roberto, Cruciani, Claudio, Quaglini, Silvana, Sacchi, Lucia, Trezzi, Barbara, Bonelli, Grazia Dea, L'Imperio, Vincenzo, Vaglio, Augusto, Furlan, Claudia, Zen, Margherita, Iaccarino, Luca, Sinico, Renato Alberto, Doria, Andrea, and Moroni, Gabriella
- Published
- 2024
- Full Text
- View/download PDF
3. Prevalence and clinical significance of ANCA positivity in lupus nephritis: a case series of 116 patients and literature review
- Author
-
Lacetera, Rosanna, Calatroni, Marta, Roggero, Letizia, Radice, Antonella, Pozzi, Maria Rosa, Reggiani, Francesco, Sciascia, Savino, Trezzi, Barbara, Roccatello, Dario, Minetti, Enrico, Moroni, Gabriella, and Sinico, Renato Alberto
- Published
- 2023
- Full Text
- View/download PDF
4. The value of the current histological scores and classifications of ANCA glomerulonephritis in predicting long-term outcome
- Author
-
Stella, Matteo, primary, Locatelli, Laura, additional, Sala, Filippo Maria, additional, Reggiani, Francesco, additional, Calatroni, Marta, additional, L'Imperio, Vincenzo, additional, Pagni, Fabio, additional, Maggiore, Umberto, additional, Moroni, Gabriella, additional, and Sinico, Renato Alberto, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Microscopic Polyangiitis
- Author
-
Sinico, Renato Alberto, Sala, Filippo Maria, Pozzi, Maria Rosa, Fabbrini, Paolo, Pieruzzi, Federico, Emmi, Lorenzo, Series Editor, Prisco, Domenico, Series Editor, Salvarani, Carlo, Editorial Board Member, Sinico, Renato Alberto, Editorial Board Member, Meroni, Pier Luigi, Editorial Board Member, Roccatello, Dario, Editorial Board Member, Matucci-Cerinic, Marco, Editorial Board Member, Gattorno, Marco, Editorial Board Member, de Benedetti, Fabrizio, Editorial Board Member, Cimaz, Rolando, Editorial Board Member, Plebani, Alessandro, Editorial Board Member, Baldari, Cosima, Editorial Board Member, D'Elios, Mario Milco, Editorial Board Member, Vaglio, Augusto, Editorial Board Member, and Guillevin, Loïc, editor
- Published
- 2020
- Full Text
- View/download PDF
6. Kidney Involvement
- Author
-
Sinico, Renato Alberto, Pagni, Fabio, L’Imperio, Vincenzo, Binda, Valentina, Fabbrini, Paolo, Pieruzzi, Federico, Moroni, Gabriella, Emmi, Lorenzo, Series Editor, Prisco, Domenico, Series Editor, Salvarani, Carlo, Editorial Board Member, Sinico, Renato Alberto, Editorial Board Member, Meroni, Pier Luigi, Editorial Board Member, Roccatello, Dario, Editorial Board Member, Matucci-Cerinic, Marco, Editorial Board Member, Gattorno, Marco, Editorial Board Member, de Benedetti, Fabrizio, Editorial Board Member, Cimaz, Rolando, Editorial Board Member, Plebani, Alessandro, Editorial Board Member, Baldari, Cosima, Editorial Board Member, D'Elios, Mario Milco, Editorial Board Member, Vaglio, Augusto, Editorial Board Member, and Guillevin, Loïc, editor
- Published
- 2020
- Full Text
- View/download PDF
7. The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult
- Author
-
Affatato, Stefania, Caroti, Leonardo, Mancini, Elena, Semeraro, Luca, Siligato, Rossella, Arnaldo Cassia, Matthias, Napodano, Pietro, Calatroni, Marta, Distratis, Cosimo, Campo, Andrea, Tedesco, Martina, Mescia, Federica, Pisani, Isabella, Allinovi, Marco, Casazza, Giovanni, Del Vecchio, Lucia, Santostefano, Marisa, Cirillo, Luigi, Ferrario, Francesca, Esposito, Ciro, Esposito, Pasquale, Santoro, Domenico, Lazzarin, Roberta, Rossi, Giovanni Maria, Fiaccadori, Enrico, Ferrantelli, Angelo, Sinico, Renato Alberto, Cozzolino, Mario, Gallieni, Maurizio, Cirami, Lino, Scolari, Francesco, Vaglio, Augusto, and Alberici, Federico
- Published
- 2022
- Full Text
- View/download PDF
8. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature
- Author
-
Pouchelon, Clara, Visentini, Marcella, Emmi, Giacomo, le Guern, Véronique, Quartuccio, Luca, Samson, Maxime, Venhoff, Nils, Briantais, Antoine, Casato, Milvia, Chatelus, Emmanuel, Chilles, Marie, Cid, Maria C., Diot, Elisabeth, Ebbo, Mikael, Faguer, Stanislas, Hellmich, Bernhard, Jachiet, Marie, Moulinet, Thomas, Perrin, François, Quémeneur, Thomas, Sinico, Renato Alberto, and Terrier, Benjamin
- Published
- 2022
- Full Text
- View/download PDF
9. Comparison of EULAR/PRINTO/PReS Ankara 2008 and 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis in children.
- Author
-
Akca, Ummusen Kaya, Batu, Ezgi Deniz, Jelusic, Marija, Calatroni, Marta, Bakry, Reima, Frkovic, Marijan, Vinšová, Nikol, Campos, Reinan T, Horne, AnnaCarin, Caglayan, Sengul, Vaglio, Augusto, Moroni, Gabriella, Emmi, Giacomo, Ghiggeri, Gian Marco, Koker, Oya, Sinico, Renato Alberto, Kim, Susan, Gagro, Alenka, Matucci-Cerinic, Caterina, and Çomak, Elif
- Subjects
PREDICTIVE tests ,SCHOENLEIN-Henoch purpura ,MICROSCOPIC polyangiitis ,RETROSPECTIVE studies ,BEHCET'S disease ,COGAN syndrome ,GRANULOMATOSIS with polyangiitis ,PEDIATRICS ,MEDICAL records ,ACQUISITION of data ,TAKAYASU arteritis ,SENSITIVITY & specificity (Statistics) ,POLYARTERITIS nodosa ,CHILDREN - Abstract
Objective Granulomatosis with polyangiitis (GPA) is an ANCA-associated vasculitis. The 2022 ACR/EULAR-endorsed classification criteria for GPA was derived using data only from adult patients. We aimed to assess the performance of the ACR/EULAR classification criteria for GPA in paediatric patients and compare it with the EULAR/Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology European Society (PReS)-endorsed Ankara 2008 criteria for GPA. Methods Retrospective data of paediatric patients with GPA in 20 centres from 9 countries were evaluated. The diagnosis of GPA was made according to the expert opinion. The sensitivity, specificity, positive predictive value, and negative predictive value of the criteria sets were evaluated. Results The study included 77 patients with GPA and 108 controls [IgA vasculitis (n = 44), Takayasu's arteritis (n = 20), microscopic polyangiitis (n = 16), polyarteritis nodosa (n = 14), Behçet's disease (n = 12), eosinophilic granulomatosis with polyangiitis (n = 1) and Cogan's syndrome (n = 1)] with a median age of 17.8 and 15.2 years, respectively. Among patients with GPA, constitutional symptoms (85.7%) and ENT involvement (79.2%) were the most common presentations. In the GPA group, 73 patients fulfilled the Ankara 2008 criteria and 69 the ACR/EULAR classification criteria. Sensitivities of the Ankara 2008 criteria and the ACR/EULAR classification criteria were 94.8% and 89.6%, while specificities were 95.3% and 96.3%, respectively. No significant difference was found between sensitivities and specificities of both classification criteria (P = 0.229 and P = 0.733, respectively). Conclusion In children, both the ACR/EULAR and EULAR/PRINTO/PReS Ankara 2008 classification criteria for GPA perform well and similarly. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Destructuring glomerular diseases with structured deposits: challenges in the precision medicine era
- Author
-
L’Imperio, Vincenzo, Barreca, Antonella, Vergani, Barbara, Sinico, Renato Alberto, and Pagni, Fabio
- Published
- 2021
- Full Text
- View/download PDF
11. Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons
- Author
-
Reggiani, Francesco, primary, Stella, Matteo, additional, Calatroni, Marta, additional, and Sinico, Renato Alberto, additional
- Published
- 2024
- Full Text
- View/download PDF
12. O25 Lupus podocytopathy: a rare form of lupus nephritis – an Italian retrospective multicenter study
- Author
-
Bonelli, Grazia Dea, primary, Sciascia, Savino, additional, Calatroni, Marta, additional, L’imperio, Vincenzo, additional, Reggiani, Francesco, additional, Fenoglio, Roberta, additional, Argolini, Lorenza, additional, Carrara, Camillo, additional, Lepori, Nicola, additional, Catapano, Fausta, additional, Gatto, Mariele, additional, Tani, Chiara, additional, Santoro, Domenico, additional, Gerosa, Maria, additional, Mosca, Marta, additional, Roccatello, Dario, additional, Sinico, Renato Alberto, additional, and Moroni, Gabriella, additional
- Published
- 2024
- Full Text
- View/download PDF
13. O43 Three years is the minimal effective duration of sustained clinical remission associated with reduced risk of impaired kidney function and of damage accrual in lupus nephritis
- Author
-
Gatto, Mariele, primary, Frontini, Giulia, additional, Calatroni, Marta, additional, Cruciani, Claudio, additional, Iaccarino, Luca, additional, Reggiani, Francesco, additional, Sinico, Renato Alberto, additional, Moroni, Gabriella, additional, and Doria, Andrea, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Comparison of EULAR/PRINTO/PReS Ankara 2008 and 2022 ACR/EULAR Classification Criteria for Granulomatosis with Polyangiitis in Children
- Author
-
Kaya Akca, Ummusen, primary, Batu, Ezgi Deniz, additional, Jelusic, Marija, additional, Calatroni, Marta, additional, Bakry, Reima, additional, Frkovic, Marijan, additional, Vinšová, Nikol, additional, Campos, Reinan T, additional, Horne, AnnaCarin, additional, Caglayan, Sengul, additional, Vaglio, Augusto, additional, Moroni, Gabriella, additional, Emmi, Giacomo, additional, Ghiggeri, Gian Marco, additional, Koker, Oya, additional, Sinico, Renato Alberto, additional, Kim, Susan, additional, Gagro, Alenka, additional, Matucci-Cerinic, Caterina, additional, Çomak, Elif, additional, Ekici Tekin, Zahide, additional, Arslanoglu Aydin, Elif, additional, Heshin-Bekenstein, Merav, additional, Acar, Banu Celikel, additional, Gattorno, Marco, additional, Akman, Sema, additional, Sozeri, Betul, additional, Palmblad, Karin, additional, Al-Mayouf, Sulaiman M, additional, Silva, Clovis Artur, additional, Doležalová, Pavla, additional, Merkel, Peter A, additional, and Ozen, Seza, additional
- Published
- 2023
- Full Text
- View/download PDF
15. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient)
- Author
-
Binda, Valentina, Trezzi, Barbara, Del Papa, Nicoletta, Beretta, Lorenzo, Frontini, Giulia, Porata, Giulia, Fabbrini, Paolo, Pozzi, Maria Rosa, Messa, Piergiorgio, Sinico, Renato Alberto, and Moroni, Gabriella
- Published
- 2020
- Full Text
- View/download PDF
16. MALDI imaging in Fabry nephropathy: a multicenter study
- Author
-
L’Imperio, Vincenzo, Smith, Andrew, Pisani, Antonio, D’Armiento, Maria, Scollo, Viviana, Casano, Stefano, Sinico, Renato Alberto, Nebuloni, Manuela, Tosoni, Antonella, Pieruzzi, Federico, Magni, Fulvio, and Pagni, Fabio
- Published
- 2020
- Full Text
- View/download PDF
17. Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis
- Author
-
Rubenstein, Emma, primary, Maldini, Carla, additional, Vaglio, Augusto, additional, Bello, Federica, additional, Bremer, Jan Phillip, additional, Moosig, Frank, additional, Bottero, Paolo, additional, Pesci, Alberto, additional, Sinico, Renato Alberto, additional, Grosskreutz, Julian, additional, Feder, Claudia, additional, Saadoun, David, additional, Trivioli, Giorgio, additional, Maritati, Federica, additional, Rewerska, Barbara, additional, Szczeklik, Wojciech, additional, Fraticelli, Paolo, additional, Guida, Giuseppe, additional, Gregorini, Gina, additional, Moroncini, Gianluca, additional, Hellmich, Bernhard, additional, Zwerina, Jochen, additional, Resche-Rigon, Matthieu, additional, Emmi, Giacomo, additional, Neumann, Thomas, additional, and Mahr, Alfred, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Renal involvement in eosinophilic granulomatosis with polyangiitis
- Author
-
Reggiani, Francesco, primary, L’Imperio, Vincenzo, additional, Calatroni, Marta, additional, Pagni, Fabio, additional, and Sinico, Renato Alberto, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Towards the Definition of the Molecular Hallmarks of Idiopathic Membranous Nephropathy in Serum Proteome: A DIA-PASEF Approach
- Author
-
Previtali, Paolo, primary, Pagani, Lisa, additional, Risca, Giulia, additional, Capitoli, Giulia, additional, Bossi, Eleonora, additional, Oliveira, Glenda, additional, Piga, Isabella, additional, Radice, Antonella, additional, Trezzi, Barbara, additional, Sinico, Renato Alberto, additional, Magni, Fulvio, additional, and Chinello, Clizia, additional
- Published
- 2023
- Full Text
- View/download PDF
20. #5722 NEW ONSET OR RECURRENT GLOMERULONEPHRITIS FOLLOWING SARS-CoV2 VACCINATION: A MULTICENTER EXPERIENCE
- Author
-
Rimoldi, Chiara, primary, Gilberti, Marica, additional, Gesualdo, Loreto, additional, Sossai, Giulia, additional, Sinico, Renato Alberto, additional, Giglio, Elisa, additional, Calatroni, Marta, additional, Raimondo, Davide, additional, Gallelli, Beniamina, additional, Vecchio, Lucia Del, additional, and Visca, Sara, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Eosinophilic Granulomatosis with Polyangiitis (Churg-Straus Syndrome)
- Author
-
Sinico, Renato Alberto, Bottero, Paolo, Dammacco, Franco, editor, Ribatti, Domenico, editor, and Vacca, Angelo, editor
- Published
- 2016
- Full Text
- View/download PDF
22. Microscopic Polyangiitis
- Author
-
Sinico, Renato Alberto, primary, Sala, Filippo Maria, additional, Pozzi, Maria Rosa, additional, Fabbrini, Paolo, additional, and Pieruzzi, Federico, additional
- Published
- 2019
- Full Text
- View/download PDF
23. Kidney Involvement
- Author
-
Sinico, Renato Alberto, primary, Pagni, Fabio, additional, L’Imperio, Vincenzo, additional, Binda, Valentina, additional, Fabbrini, Paolo, additional, Pieruzzi, Federico, additional, and Moroni, Gabriella, additional
- Published
- 2019
- Full Text
- View/download PDF
24. Antiphospholipid Syndrome (APS) and the Renal Involvement
- Author
-
Mezzina, Nicoletta, Sinico, Renato Alberto, Emmi, Lorenzo, Series editor, Prisco, Domenico, Series editor, and Meroni, Pier Luigi, editor
- Published
- 2015
- Full Text
- View/download PDF
25. Anticoagulant-related nephropathy: a pathological note
- Author
-
L’Imperio, Vincenzo, Guarnieri, Alessia, Pieruzzi, Federico, Sinico, Renato Alberto, and Pagni, Fabio
- Published
- 2018
- Full Text
- View/download PDF
26. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study
- Author
-
Podesta, Manuel Alfredo, Mescia, Federica, Ricchiuto, Anna, Smith, Rona, Tedesco, Martina, Cassia, Matthias Arnaldo, Holle, Julia, Sinico, Renato Alberto, Bruchfeld, Annette, Gunnarsson, Iva, Ohlsson, Sophie, Baslund, Bo, Hruskova, Zdenka, Tesar, Vladimir, Sabiu, Gianmarco, Gallieni, Maurizio, Cid, Maria C., Vaglio, Augusto, Harper, Lorraine, Cozzolino, Mario, Scolari, Francesco, Jayne, David, Alberici, Federico, Podesta, Manuel Alfredo, Mescia, Federica, Ricchiuto, Anna, Smith, Rona, Tedesco, Martina, Cassia, Matthias Arnaldo, Holle, Julia, Sinico, Renato Alberto, Bruchfeld, Annette, Gunnarsson, Iva, Ohlsson, Sophie, Baslund, Bo, Hruskova, Zdenka, Tesar, Vladimir, Sabiu, Gianmarco, Gallieni, Maurizio, Cid, Maria C., Vaglio, Augusto, Harper, Lorraine, Cozzolino, Mario, Scolari, Francesco, Jayne, David, and Alberici, Federico
- Abstract
Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG <= 7 g/l at 6 months. Results The study included 227 patients. IgG levels at 6 months were lower than baseline (P < 0.001). Patients requiring intravenous antibiotics during the first 6 months had lower IgG levels at 6 months (P = 0.004). Age [beta (95% CI): -0.23 (-0.38, -0.08) per 10 years, P = 0.003], oral glucocorticoid dose at induction [beta (95% CI): -0.37 (-0.51, -0.24) per sqrt-transformed mg prednisone, P < 0.001] and concomitant use of intravenous glucocorticoid pulses [beta (95% CI): -0.88 (-1.73, -0.02), P = 0.044] were associated with IgG levels at 6 months. Hypogammaglobulinemia was identified in 97 (42.7%) patients. In multivariable logistic regression, factors associated with the risk of hypogammaglobulinemia were age [OR (95% CI): 1.46 (1.15, 1.86) per 10 years, P = 0.002] and oral glucocorticoid dose at induction [OR (95% CI): 1.52 (1.23, 1.89) per 10 mg prednisone, P < 0.001]. Conclusions In AAV patients treated with rituximab, hypogammaglobulinemia at 6 months after induction is common, and lower IgG levels are associated with serious infections. The risk of hypogammaglobulinemia in these patients increases with age and higher glucocorticoid doses.
- Published
- 2023
- Full Text
- View/download PDF
27. Goodpasture syndrome and anti-glomerular basement membrane disease
- Author
-
Reggiani, F, L'Imperio, V, Calatroni, M, Pagni, F, Sinico, R, Reggiani, Francesco, L'Imperio, Vincenzo, Calatroni, Marta, Pagni, Fabio, Sinico, Renato Alberto, Reggiani, F, L'Imperio, V, Calatroni, M, Pagni, F, Sinico, R, Reggiani, Francesco, L'Imperio, Vincenzo, Calatroni, Marta, Pagni, Fabio, and Sinico, Renato Alberto
- Abstract
Anti-glomerular basement membrane (anti-GBM) disease is a rare life-threatening small vessel vasculitis that typically affects the capillaries of kidneys and lungs, with most of patients developing rapidly progressive crescentic glomerulonephritis, and 40%-60% concomitant alveolar haemorrhage. It is caused by the deposition in alveolar and glomerular basement membrane of circulating autoantibodies directed against antigens intrinsic to the basement membrane. The exact mechanism that induces the formation of autoantibodies is unknown, but probably environmental factors, infections or direct damage to kidneys and lungs may trigger the autoimmune response in genetically susceptible individuals. Initial therapy includes corticosteroids and cyclophosphamide to prevent autoantibodies production, and plasmapheresis to remove the circulating autoantibodies. Good renal outcomes may be achieved by a prompt treatment initiation. However, when patients present with severe renal failure requiring dialysis or with a high proportion of glomerular crescents at biopsy, renal outcomes are bad. Relapses are rare and when renal involvement is present, the suspect of concomitant diseases, such as ANCA-associated vasculitis and membranous nephropathy, should be raised. Imlifidase is showing promising results, which if confirmed will cause a paradigm shift in the treatment of this disease.
- Published
- 2023
28. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction:a multicentre study
- Author
-
Podesta, Manuel Alfredo, Mescia, Federica, Ricchiuto, Anna, Smith, Rona, Tedesco, Martina, Cassia, Matthias Arnaldo, Holle, Julia, Sinico, Renato Alberto, Bruchfeld, Annette, Gunnarsson, Iva, Ohlsson, Sophie, Baslund, Bo, Hruskova, Zdenka, Tesar, Vladimir, Sabiu, Gianmarco, Gallieni, Maurizio, Cid, Maria C., Vaglio, Augusto, Harper, Lorraine, Cozzolino, Mario, Scolari, Francesco, Jayne, David, Alberici, Federico, Podesta, Manuel Alfredo, Mescia, Federica, Ricchiuto, Anna, Smith, Rona, Tedesco, Martina, Cassia, Matthias Arnaldo, Holle, Julia, Sinico, Renato Alberto, Bruchfeld, Annette, Gunnarsson, Iva, Ohlsson, Sophie, Baslund, Bo, Hruskova, Zdenka, Tesar, Vladimir, Sabiu, Gianmarco, Gallieni, Maurizio, Cid, Maria C., Vaglio, Augusto, Harper, Lorraine, Cozzolino, Mario, Scolari, Francesco, Jayne, David, and Alberici, Federico
- Abstract
Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG
- Published
- 2023
29. Goodpasture syndrome and anti-glomerular basement membrane disease
- Author
-
Reggiani, Francesco, L'Imperio, Vincenzo, Calatroni, Marta, Pagni, Fabio, Sinico, Renato Alberto, Reggiani, F, L'Imperio, V, Calatroni, M, Pagni, F, and Sinico, R
- Subjects
Rheumatology ,renal pathology ,Immunology ,Immunology and Allergy - Abstract
Anti-glomerular basement membrane (anti-GBM) disease is a rare life-threatening small vessel vasculitis that typically affects the capillaries of kidneys and lungs, with most of patients developing rapidly progressive crescentic glomerulonephritis, and 40%-60% concomitant alveolar haemorrhage. It is caused by the deposition in alveolar and glomerular basement membrane of circulating autoantibodies directed against antigens intrinsic to the basement membrane. The exact mechanism that induces the formation of autoantibodies is unknown, but probably environmental factors, infections or direct damage to kidneys and lungs may trigger the autoimmune response in genetically susceptible individuals. Initial therapy includes corticosteroids and cyclophosphamide to prevent autoantibodies production, and plasmapheresis to remove the circulating autoantibodies. Good renal outcomes may be achieved by a prompt treatment initiation. However, when patients present with severe renal failure requiring dialysis or with a high proportion of glomerular crescents at biopsy, renal outcomes are bad. Relapses are rare and when renal involvement is present, the suspect of concomitant diseases, such as ANCA-associated vasculitis and membranous nephropathy, should be raised. Imlifidase is showing promising results, which if confirmed will cause a paradigm shift in the treatment of this disease.
- Published
- 2023
30. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient)
- Author
-
Binda, Valentina, Trezzi, Barbara, Del Papa, Nicoletta, Beretta, Lorenzo, Frontini, Giulia, Porata, Giulia, Fabbrini, Paolo, Pozzi, Maria Rosa, Messa, Piergiorgio, Sinico, Renato Alberto, and Moroni, Gabriella
- Abstract
Background: Belimumab (Benlysta) is currently approved for the treatment of active Lupus despite standard therapy. Few data are available on the efficacy of this drug in lupus nephritis (LN). Methods: 17 LN female followed in two Nephrology Italian Unit received belimumab for a median period of 36 months (range 6–42 months). The indications were: arthralgia in 3 patients, cutaneous manifestations in 2, residual proteinuria in 8, and the need to reduce steroids for severe side effects in 4. Of interest, 1 patient started therapy during Peritoneal Dialysis and continued after kidney transplantation due to non-responsive arthralgias. Results: Arthralgia and skin manifestations resolved in all patients. Proteinuria normalized in three patients and stabilized in all but one of the others. Steroids were indefinitely stopped in six patients (35%) and reduced to around 40% of the basal dosage in the other patients. During belimumab therapy, three extrarenal and one renal SLE flares were diagnosed accounting for a rate of renal flares of 0.02/patient/year. No major adverse events leading to therapy withdrawal occurred. Clinical case: Arthralgia resolved, immunological parameters improved and prednisone could be reduced within few months in the patient who started belimumab during peritoneal dialysis. After kidney transplantation belimumab was stopped but due to arthralgias unresponsive to standard immunosuppressive therapy it was restarted with success. Conclusions: Belimumab allows the achievement of complete response together with the withdrawal or the reduction of corticosteroids in almost all our patients. Of interest its satisfactory use in a patient in peritoneal dialysis and after kidney transplantation.
- Published
- 2024
- Full Text
- View/download PDF
31. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study
- Author
-
Podestà, Manuel Alfredo, primary, Mescia, Federica, additional, Ricchiuto, Anna, additional, Smith, Rona, additional, Tedesco, Martina, additional, Cassia, Matthias Arnaldo, additional, Holle, Julia, additional, Sinico, Renato Alberto, additional, Bruchfeld, Annette, additional, Gunnarsson, Iva, additional, Ohlsson, Sophie, additional, Baslund, Bo, additional, Hruskova, Zdenka, additional, Tesar, Vladimir, additional, Sabiu, Gianmarco, additional, Gallieni, Maurizio, additional, Cid, Maria C, additional, Vaglio, Augusto, additional, Harper, Lorraine, additional, Cozzolino, Mario, additional, Scolari, Francesco, additional, Jayne, David, additional, and Alberici, Federico, additional
- Published
- 2022
- Full Text
- View/download PDF
32. Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence?
- Author
-
Lacetera, Rosanna, primary, Roggero, Letizia, additional, Vercelloni, Paolo, additional, Uzzo, Martina, additional, Carbone, Marco, additional, Invernizzi, Pietro, additional, L’Imperio, Vincenzo, additional, Pieruzzi, Federico, additional, and Sinico, Renato Alberto, additional
- Published
- 2022
- Full Text
- View/download PDF
33. Evidence for charge-based mimicry in anti dsDNA antibody generation
- Author
-
Bruschi, Maurizio, primary, Angeletti, Andrea, additional, Kajana, Xhuliana, additional, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Fredi, Micaela, additional, Vaglio, Augusto, additional, Cavagna, Lorenzo, additional, Pratesi, Federico, additional, Migliorini, Paola, additional, Locatelli, Francesco, additional, Pazzola, Giulia, additional, Pesce, Giampaola, additional, Bagnasco, Marcello, additional, Manfredi, Angelo, additional, Ramirez, Giuseppe Alvise, additional, Esposito, Pasquale, additional, Negrini, Simone, additional, Bui, Federica, additional, Trezzi, Barbara, additional, Emmi, Giacomo, additional, Cavazzana, Ilaria, additional, Binda, Valentina, additional, Fenaroli, Paride, additional, Pisani, Isabella, additional, Montecucco, Carlomaurizio, additional, Santoro, Domenico, additional, Scolari, Francesco, additional, Volpi, Stefano, additional, Mosca, Marta, additional, Tincani, Angela, additional, Candiano, Giovanni, additional, Verrina, Enrico, additional, Franceschini, Franco, additional, Ravelli, Angelo, additional, Prunotto, Marco, additional, Meroni, Pier Luigi, additional, and Ghiggeri, Gian Marco, additional
- Published
- 2022
- Full Text
- View/download PDF
34. Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination
- Author
-
Ramirez, Giuseppe A, primary, Argolini, Lorenza Maria, additional, Schioppo, Tommaso, additional, Sciascia, Savino, additional, Moroni, Luca, additional, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Bonelli, Grazia, additional, Alberici, Federico, additional, Mescia, Federica, additional, Tamborini, Francesco, additional, Miraglia, Paolo, additional, Bellocchi, Chiara, additional, Beretta, Lorenzo, additional, Roccatello, Dario, additional, Bozzolo, Enrica Paola, additional, Caporali, Roberto, additional, Gerosa, Maria, additional, and Dagna, Lorenzo, additional
- Published
- 2022
- Full Text
- View/download PDF
35. The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult
- Author
-
Tedesco, Martina, primary, Mescia, Federica, additional, Pisani, Isabella, additional, Allinovi, Marco, additional, Casazza, Giovanni, additional, Del Vecchio, Lucia, additional, Santostefano, Marisa, additional, Cirillo, Luigi, additional, Ferrario, Francesca, additional, Esposito, Ciro, additional, Esposito, Pasquale, additional, Santoro, Domenico, additional, Lazzarin, Roberta, additional, Rossi, Giovanni Maria, additional, Fiaccadori, Enrico, additional, Ferrantelli, Angelo, additional, Sinico, Renato Alberto, additional, Cozzolino, Mario, additional, Gallieni, Maurizio, additional, Cirami, Lino, additional, Scolari, Francesco, additional, Vaglio, Augusto, additional, Alberici, Federico, additional, Affatato, Stefania, additional, Caroti, Leonardo, additional, Mancini, Elena, additional, Semeraro, Luca, additional, Siligato, Rossella, additional, Arnaldo Cassia, Matthias, additional, Napodano, Pietro, additional, Calatroni, Marta, additional, Distratis, Cosimo, additional, and Campo, Andrea, additional
- Published
- 2022
- Full Text
- View/download PDF
36. POSITION PAPER: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
- Author
-
Bossuyt, Xavier, Tervaert, Jan-Willem Cohen, Arimura, Yoshihiro, Blockmans, Daniel, Flores-Suárez, Luis Felipe, Guillevin, Loïc, Hellmich, Bernhard, Jayne, David, Jennette, Charles J., Kallenberg, Cees G. M., Moiseev, Sergey, Novikov, Pavel, Radice, Antonella, Savige, Judith Anne, Sinico, Renato Alberto, Specks, Ulrich, Paassen, Pieter van, Zhao, Ming-hui, Rasmussen, Niels, Damoiseaux, Jan, and Csernok, Elena
- Published
- 2017
- Full Text
- View/download PDF
37. Long-term kidney outcome of patients with rheumatological diseases and antineutrophil cytoplasmic antibody-glomerulonephritis: comparison with a primitive ANCA-glomerulonephritis cohort
- Author
-
Locatelli, Laura, primary, Calatroni, Marta, additional, Reggiani, Francesco, additional, Bonelli, Grazia Dea, additional, Gerosa, Maria, additional, Argolini, Lorenza Maria, additional, Trezzi, Barbara, additional, Del Papa, Nicoletta, additional, Angelini, Claudio, additional, Pozzi, Maria Rosa, additional, Sinico, Renato Alberto, additional, and Moroni, Gabriella, additional
- Published
- 2022
- Full Text
- View/download PDF
38. Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
- Author
-
Gatto, Mariele, primary, Radice, Francesca, additional, Saccon, Francesca, additional, Calatroni, Marta, additional, Frontini, Giulia, additional, Trezzi, Barbara, additional, Zen, Margherita, additional, Ghirardello, Anna, additional, Tamborini, Francesco, additional, Binda, Valentina, additional, L'Imperio, Vincenzo, additional, Doria, Andrea, additional, Vaglio, Augusto, additional, Sinico, Renato Alberto, additional, Moroni, Gabriella, additional, and Iaccarino, Luca, additional
- Published
- 2022
- Full Text
- View/download PDF
39. Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy:Aberrant IgG Glycoforms in Blood
- Author
-
Chinello, Clizia, de Haan, Noortje, Capitoli, Giulia, Trezzi, Barbara, Radice, Antonella, Pagani, Lisa, Criscuolo, Lucrezia, Signorini, Stefano, Galimberti, Stefania, Sinico, Renato Alberto, Wuhrer, Manfred, Magni, Fulvio, Chinello, Clizia, de Haan, Noortje, Capitoli, Giulia, Trezzi, Barbara, Radice, Antonella, Pagani, Lisa, Criscuolo, Lucrezia, Signorini, Stefano, Galimberti, Stefania, Sinico, Renato Alberto, Wuhrer, Manfred, and Magni, Fulvio
- Abstract
The podocyte injury, and consequent proteinuria, that characterize the pathology of idiopathic membranous nephropathy (IMN) is mediated by an autoimmune reaction against podocyte antigens. In particular, the activation of pathways leading to abundant renal deposits of complement is likely to involve the binding of mannose-binding lectin (MBL) to aberrant glycans on immunoglobulins. To obtain a landscape of circulatory IgG Fc glycosylation characterizing this disease, we conducted a systematic N-glycan profiling study of IgG1, 2, and 4 by mass spectrometry. The cohort included 57 IMN patients, a pathological control group with nephrotic syndrome (PN) (n = 20), and 88 healthy control subjects. The effect of sex and age was assessed in all groups and controlled by rigorous matching. Several IgG Fc glycan traits were found to be associated with IMN. Interestingly, among them, only IgG4-related results were specific for IMN and not for PN. Hypogalactosylation of IgG4, already shown for IMN, was observed to occur in the absence of core fucose, in line with a probable increase of pro-inflammatory IgG. In addition, elevated levels of fucosylated IgG4, along with low levels of hybrid-type glycans, were detected. Some of these IgG4 alterations are likely to be more pronounced in high PLA2R (phospholipase A2 receptor) patients. IgG Fc glycosylation patterns associated with IMN warrant further studies of their role in disease mechanisms and may eventually enrich the diagnostic spectrum regarding patient stratification.
- Published
- 2022
40. Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood
- Author
-
Chinello, C, de Haan, N, Capitoli, G, Trezzi, B, Radice, A, Pagani, L, Criscuolo, L, Signorini, S, Galimberti, S, Sinico, R, Wuhrer, M, Magni, F, Chinello, Clizia, de Haan, Noortje, Capitoli, Giulia, Trezzi, Barbara, Radice, Antonella, Pagani, Lisa, Criscuolo, Lucrezia, Signorini, Stefano, Galimberti, Stefania, Sinico, Renato Alberto, Wuhrer, Manfred, Magni, Fulvio, Chinello, C, de Haan, N, Capitoli, G, Trezzi, B, Radice, A, Pagani, L, Criscuolo, L, Signorini, S, Galimberti, S, Sinico, R, Wuhrer, M, Magni, F, Chinello, Clizia, de Haan, Noortje, Capitoli, Giulia, Trezzi, Barbara, Radice, Antonella, Pagani, Lisa, Criscuolo, Lucrezia, Signorini, Stefano, Galimberti, Stefania, Sinico, Renato Alberto, Wuhrer, Manfred, and Magni, Fulvio
- Abstract
The podocyte injury, and consequent proteinuria, that characterize the pathology of idiopathic membranous nephropathy (IMN) is mediated by an autoimmune reaction against podocyte antigens. In particular, the activation of pathways leading to abundant renal deposits of complement is likely to involve the binding of mannose-binding lectin (MBL) to aberrant glycans on immunoglobulins. To obtain a landscape of circulatory IgG Fc glycosylation characterizing this disease, we conducted a systematic N-glycan profiling study of IgG1, 2, and 4 by mass spectrometry. The cohort included 57 IMN patients, a pathological control group with nephrotic syndrome (PN) (n = 20), and 88 healthy control subjects. The effect of sex and age was assessed in all groups and controlled by rigorous matching. Several IgG Fc glycan traits were found to be associated with IMN. Interestingly, among them, only IgG4-related results were specific for IMN and not for PN. Hypogalactosylation of IgG4, already shown for IMN, was observed to occur in the absence of core fucose, in line with a probable increase of pro-inflammatory IgG. In addition, elevated levels of fucosylated IgG4, along with low levels of hybrid-type glycans, were detected. Some of these IgG4 alterations are likely to be more pronounced in high PLA2R (phospholipase A2 receptor) patients. IgG Fc glycosylation patterns associated with IMN warrant further studies of their role in disease mechanisms and may eventually enrich the diagnostic spectrum regarding patient stratification.
- Published
- 2022
41. Evidence for charge-based mimicry in anti dsDNA antibody generation
- Author
-
Bruschi, M, Angeletti, A, Kajana, X, Moroni, G, Sinico, R, Fredi, M, Vaglio, A, Cavagna, L, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Bui, F, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Verrina, E, Franceschini, F, Ravelli, A, Prunotto, M, Meroni, P, Ghiggeri, G, Bruschi, Maurizio, Angeletti, Andrea, Kajana, Xhuliana, Moroni, Gabriella, Sinico, Renato Alberto, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe Alvise, Esposito, Pasquale, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Verrina, Enrico, Franceschini, Franco, Ravelli, Angelo, Prunotto, Marco, Meroni, Pier Luigi, Ghiggeri, Gian Marco, Bruschi, M, Angeletti, A, Kajana, X, Moroni, G, Sinico, R, Fredi, M, Vaglio, A, Cavagna, L, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Bui, F, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Verrina, E, Franceschini, F, Ravelli, A, Prunotto, M, Meroni, P, Ghiggeri, G, Bruschi, Maurizio, Angeletti, Andrea, Kajana, Xhuliana, Moroni, Gabriella, Sinico, Renato Alberto, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe Alvise, Esposito, Pasquale, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Verrina, Enrico, Franceschini, Franco, Ravelli, Angelo, Prunotto, Marco, Meroni, Pier Luigi, and Ghiggeri, Gian Marco
- Abstract
Mechanisms for the generation of anti-dsDNA autoantibodies are still not completely elucidated. One theory states that dsDNA interacts for mimicry with antibodies raised versus other antigens but molecular features for mimicry are unknown. Here we show that, at physiological acid-base balance, anti-Annexin A1 binds IgG2 dsDNA in a competitive and dose-dependent way with Annexin A1 and that the competition between the two molecules is null at pH 9. On the other hand, these findings also show that dsDNA and Annexin A1 interact with their respective antibodies on a strictly pH-dependent basis: in both cases, the binding was minimal at pH 4 and maximal at pH9-10. The anionic charge of dsDNA is mainly conferred by the numerous phosphatidic residues. The epitope binding site of Annexin A1 for anti-Annexin A1 IgG2 was here characterized as a string of 34 amino acids at the NH2 terminus, 10 of which are anionic. Circulating levels of anti-dsDNA and anti-Annexin A1 IgG2 antibodies were strongly correlated in patients with systemic lupus erythematosus (n 496) and lupus nephritis (n 425) stratified for age, sex, etc. These results show that dsDNA competes with Annexin A1 for the binding with anti-Annexin A1 IgG2 on a dose and charged mediated base, being able to display an inhibition up to 75%. This study provides the first demonstration that dsDNA may interact with antibodies raised versus other anionic molecules (anti-Annexin A1 IgG2) because of charge mimicry and this interaction may contribute to anti-dsDNA antibodies generation.
- Published
- 2022
42. The Role of Rituximab in Primary Focal Segmental Glomerulosclerosis of the Adult
- Author
-
Tedesco, M, Mescia, F, Pisani, I, Allinovi, M, Casazza, G, Del Vecchio, L, Santostefano, M, Cirillo, L, Ferrario, F, Esposito, C, Esposito, P, Santoro, D, Lazzarin, R, Rossi, G, Fiaccadori, E, Ferrantelli, A, Sinico, R, Cozzolino, M, Gallieni, M, Cirami, L, Scolari, F, Vaglio, A, Alberici, F, Affatato, S, Caroti, L, Mancini, E, Semeraro, L, Siligato, R, Cassia, M, Napodano, P, Calatroni, M, Distratis, C, Campo, A, Tedesco, Martina, Mescia, Federica, Pisani, Isabella, Allinovi, Marco, Casazza, Giovanni, Del Vecchio, Lucia, Santostefano, Marisa, Cirillo, Luigi, Ferrario, Francesca, Esposito, Ciro, Esposito, Pasquale, Santoro, Domenico, Lazzarin, Roberta, Rossi, Giovanni Maria, Fiaccadori, Enrico, Ferrantelli, Angelo, Sinico, Renato Alberto, Cozzolino, Mario, Gallieni, Maurizio, Cirami, Lino, Scolari, Francesco, Vaglio, Augusto, Alberici, Federico, Affatato, Stefania, Caroti, Leonardo, Mancini, Elena, Semeraro, Luca, Siligato, Rossella, Cassia, Matthias Arnaldo, Napodano, Pietro, Calatroni, Marta, Distratis, Cosimo, Campo, Andrea, Tedesco, M, Mescia, F, Pisani, I, Allinovi, M, Casazza, G, Del Vecchio, L, Santostefano, M, Cirillo, L, Ferrario, F, Esposito, C, Esposito, P, Santoro, D, Lazzarin, R, Rossi, G, Fiaccadori, E, Ferrantelli, A, Sinico, R, Cozzolino, M, Gallieni, M, Cirami, L, Scolari, F, Vaglio, A, Alberici, F, Affatato, S, Caroti, L, Mancini, E, Semeraro, L, Siligato, R, Cassia, M, Napodano, P, Calatroni, M, Distratis, C, Campo, A, Tedesco, Martina, Mescia, Federica, Pisani, Isabella, Allinovi, Marco, Casazza, Giovanni, Del Vecchio, Lucia, Santostefano, Marisa, Cirillo, Luigi, Ferrario, Francesca, Esposito, Ciro, Esposito, Pasquale, Santoro, Domenico, Lazzarin, Roberta, Rossi, Giovanni Maria, Fiaccadori, Enrico, Ferrantelli, Angelo, Sinico, Renato Alberto, Cozzolino, Mario, Gallieni, Maurizio, Cirami, Lino, Scolari, Francesco, Vaglio, Augusto, Alberici, Federico, Affatato, Stefania, Caroti, Leonardo, Mancini, Elena, Semeraro, Luca, Siligato, Rossella, Cassia, Matthias Arnaldo, Napodano, Pietro, Calatroni, Marta, Distratis, Cosimo, and Campo, Andrea
- Abstract
Introduction: Primary focal segmental glomerular sclerosis (FSGS) is a rare, likely immune-mediated disease. Rituximab (RTX) may play a role in management, although data in adults are scanty. Methods: We collected cases of RTX-treated primary FSGS within the Italian Society of Nephrology Immunopathology Working Group and explored response rate (24-hour proteinuria <3.5 g and <50% compared with baseline, stable estimated glomerular filtration rate). Results: A total of 31 patients were followed for at least 12 months; further follow-up (median 17 months, interquartile range [IQR] 15–33.5) was available for 11. At first RTX administration, median creatinine and 24-hour proteinuria were 1.17 mg/dl (IQR 0.83–1.62) and 5.2 g (IQR 3.3–8.81), respectively. Response rate at 3, 6, and 12 months was 39%, 52%, and 42%, respectively. In the first 12 months, creatinine level remained stable whereas proteinuria and serum albumin level improved, with an increase in the proportion of patients tapering other immunosuppressants. There were 6 patients who were retreated with RTX within 12 months, either for proteinuria increase or refractory disease; only the 2 responders to the first RTX course experienced a further response. At univariate analysis, 6-month response was more frequent in steroid-dependent patients (odds ratio [OR] 7.7 [95% CI 1.16–52.17]) and those with proteinuria <5 g/24 h (OR 8.25 [1.45–46.86]). During long-term follow-up, 4 of 5 responders at 12 months maintained a sustained response, either without further immunosuppression (2 of 4) or with pre-emptive RTX (2 of 4); 1 relapsed and responded to RTX retreatment. Conclusion: RTX may be an option in primary FSGS, especially in steroid-dependent patients, with 24-hour proteinuria <5 g and previously responders to RTX. Optimal long-term management for responders is unclear, with some patients experiencing sustained remission and others requiring RTX retreatment, either preemptive or after rising proteinuria
- Published
- 2022
43. Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients
- Author
-
Schioppo, T, Argolini, L, Sciascia, S, Pregnolato, F, Tamborini, F, Miraglia, P, Roccatello, D, Sinico, R, Caporali, R, Moroni, G, Gerosa, M, Schioppo, Tommaso, Argolini, Lorenza Maria, Sciascia, Savino, Pregnolato, Francesca, Tamborini, Francesco, Miraglia, Paolo, Roccatello, Dario, Sinico, Renato Alberto, Caporali, Roberto, Moroni, Gabriella, Gerosa, Maria, Schioppo, T, Argolini, L, Sciascia, S, Pregnolato, F, Tamborini, F, Miraglia, P, Roccatello, D, Sinico, R, Caporali, R, Moroni, G, Gerosa, M, Schioppo, Tommaso, Argolini, Lorenza Maria, Sciascia, Savino, Pregnolato, Francesca, Tamborini, Francesco, Miraglia, Paolo, Roccatello, Dario, Sinico, Renato Alberto, Caporali, Roberto, Moroni, Gabriella, and Gerosa, Maria
- Abstract
Objectives: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with SLE remains unclear and data on clinical manifestations after infection are lacking. The aim of this multicentre study is to describe the effect of SARS-CoV-2 in SLE patients. Methods: SLE patients referring to four Italian centres were monitored between February 2020 and March 2021. All patients with SARS-CoV-2 infection were included. Disease characteristics, treatment, disease activity and SARS-CoV-2-related symptoms were recorded before and after the infection. Results: Fifty-one (6.14%) SLE patients were included among 830 who were regularly followed up. Nine (17.6%) had an asymptomatic infection and 5 (9.8%) out of 42 (82.6%) symptomatic patients developed interstitial pneumonia (no identified risk factor). The presence of SLE major organ involvement (particularly renal involvement) was associated with asymptomatic SARS-CoV-2 infection (P = 0.02). Chronic corticosteroid therapy was found to be associated with asymptomatic infection (P = 0.018). Three SLE flares (5.9%) were developed after SARS-CoV-2 infection: one of them was characterized by MPO-ANCA-positive pauci-immune crescentic necrotizing glomerulonephritis and granulomatous pneumonia. Conclusions: SARS-CoV-2 infection determined autoimmune flares in a small number of patients. Our data seem to confirm that there was not an increased risk of SARS-CoV-2 in SLE. Patients with asymptomatic SARS-CoV-2 infections were those having major SLE organ involvement. This may be explained by the high doses of corticosteroids and immunosuppressive agents used for SLE treatment.
- Published
- 2022
44. Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
- Author
-
Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Urban, Maria Letizia, Dagna, Lorenzo, Cottin, Vincent, Franceschini, Franco, Del Giacco, Stefano, Schiavon, Franco, Neumann, Thomas, Lopalco, Giuseppe, Novikov, Pavel, Baldini, Chiara, Lombardi, Carlo, Berti, Alvise, Alberici, Federico, Folci, Marco, Negrini, Simone, Sinico, Renato Alberto, Quartuccio, Luca, Lunardi, Claudio, Parronchi, Paola, Moosig, Frank, Espígol-Frigolé, Georgina, Schroeder, Jan, Kernder, Anna Luise, Monti, Sara, Silvagni, Ettore, Crimi, Claudia, Cinetto, Francesco, Fraticelli, Paolo, Roccatello, Dario, Vacca, Angelo, Mohammad, Aladdin J, Hellmich, Bernhard, Samson, Maxime, Bargagli, Elena, Cohen Tervaert, Jan Willem, Ribi, Camillo, Fiori, Davide, Bello, Federica, Fagni, Filippo, Moroni, Luca, Ramirez, Giuseppe Alvise, Nasser, Mouhamad, Marvisi, Chiara, Toniati, Paola, Firinu, Davide, Padoan, Roberto, Egan, Allyson, Seeliger, Benjamin, Iannone, Florenzo, Salvarani, Carlo, Jayne, David, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo, Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Urban, Maria Letizia, Dagna, Lorenzo, Cottin, Vincent, Franceschini, Franco, Del Giacco, Stefano, Schiavon, Franco, Neumann, Thomas, Lopalco, Giuseppe, Novikov, Pavel, Baldini, Chiara, Lombardi, Carlo, Berti, Alvise, Alberici, Federico, Folci, Marco, Negrini, Simone, Sinico, Renato Alberto, Quartuccio, Luca, Lunardi, Claudio, Parronchi, Paola, Moosig, Frank, Espígol-Frigolé, Georgina, Schroeder, Jan, Kernder, Anna Luise, Monti, Sara, Silvagni, Ettore, Crimi, Claudia, Cinetto, Francesco, Fraticelli, Paolo, Roccatello, Dario, Vacca, Angelo, Mohammad, Aladdin J, Hellmich, Bernhard, Samson, Maxime, Bargagli, Elena, Cohen Tervaert, Jan Willem, Ribi, Camillo, Fiori, Davide, Bello, Federica, Fagni, Filippo, Moroni, Luca, Ramirez, Giuseppe Alvise, Nasser, Mouhamad, Marvisi, Chiara, Toniati, Paola, Firinu, Davide, Padoan, Roberto, Egan, Allyson, Seeliger, Benjamin, Iannone, Florenzo, Salvarani, Carlo, Jayne, David, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo
- Abstract
Objective: Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort. Methods: We included all EGPA patients treated with mepolizumab at the recruiting centres in 2015-2020. Treatment response was evaluated from month 3 through 24 (T3-T24) after mepolizumab starting. Complete response (CR) was defined as no disease activity (Birmingham Vasculitis Activity Score, BVAS=0) and a prednisone dose ≤4mg/day. Respiratory outcomes included asthma and ear-nose-throat (ENT) exacerbations. Results: We included 203 patients, of whom 191 at stable dosage (158 mepolizumab 100mg/4 weeks, 33 300mg/4 weeks). At T3, 25 patients (12.3%) had a CR. CR rates increased to 30.4% and 35.7% at T12 and T24 and were comparable between mepolizumab 100 and 300mg/4 weeks. Mepolizumab led to a significant reduction in BVAS, prednisone dose, eosinophil counts from T3 through T24, with no significant differences between 100 and 300 mg/4weeks. Eighty-two patients (40.4%) experienced asthma exacerbations [57/158 (36%) on 100mg/4 weeks; 17/33 (52%) on 300mg/4 weeks]. Thirty-one (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events, most being non-serious (38/44). Conclusion: Mepolizumab both at 100 and 300mg/4 weeks is effective for EGPA. The two dosages should be compared in the setting of a controlled trial.
- Published
- 2022
45. The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study
- Author
-
Gerosa, M, Schioppo, T, Argolini, L, Sciascia, S, Ramirez, G, Moroni, G, Sinico, R, Bonelli, G, Alberici, F, Mescia, F, Moroni, L, Tamborini, F, Miraglia, P, Bellocchi, C, Beretta, L, Roccatello, D, Dagna, L, Bozzolo, E, Caporali, R, Gerosa, Maria, Schioppo, Tommaso, Argolini, Lorenza Maria, Sciascia, Savino, Ramirez, Giuseppe Alvise, Moroni, Gabriella, Sinico, Renato Alberto, Bonelli, Grazia, Alberici, Federico, Mescia, Federica, Moroni, Luca, Tamborini, Francesco, Miraglia, Paolo, Bellocchi, Chiara, Beretta, Lorenzo, Roccatello, Dario, Dagna, Lorenzo, Bozzolo, Enrica, Caporali, Roberto, Gerosa, M, Schioppo, T, Argolini, L, Sciascia, S, Ramirez, G, Moroni, G, Sinico, R, Bonelli, G, Alberici, F, Mescia, F, Moroni, L, Tamborini, F, Miraglia, P, Bellocchi, C, Beretta, L, Roccatello, D, Dagna, L, Bozzolo, E, Caporali, R, Gerosa, Maria, Schioppo, Tommaso, Argolini, Lorenza Maria, Sciascia, Savino, Ramirez, Giuseppe Alvise, Moroni, Gabriella, Sinico, Renato Alberto, Bonelli, Grazia, Alberici, Federico, Mescia, Federica, Moroni, Luca, Tamborini, Francesco, Miraglia, Paolo, Bellocchi, Chiara, Beretta, Lorenzo, Roccatello, Dario, Dagna, Lorenzo, Bozzolo, Enrica, and Caporali, Roberto
- Abstract
Vulnerable subjects, including systemic lupus erythematosus (SLE) patients, have been prioritised to receive anti-SARS-CoV-2 vaccines. Few data about the safety of these vaccines in SLE are available. The aim of our study is to investigate the safety of anti-SARS-CoV-2 vaccines in SLE. We included 452 SLE patients, referring to seven tertiary centres, who were immunised. A total of 119 (26%) reported side effects (SE) after the first and/or the second shot (the most frequent SE were fever, local reaction, fatigue, and arthralgia). Patients with constitutional symptoms and those on an immunosuppressive regimen (especially belimumab) showed more SE. In addition, 19 (4%) had a flare after the immunisation (flares classified by organ involvement: six musculoskeletal with constitutional symptoms, four renal, three cardio-respiratory, three haematological, two mucocutaneous). None of the patients needed hospitalisation and none died. Moreover, 15 required a transient increase in corticosteroids and four were treated with steroid pulses. One patient required an additional rituximab course. Anti-dsDNA, moderate/high DAS before vaccine, and belimumab were found more frequently in patients with disease flare. Anti-SARS-CoV-2 vaccines are safe in SLE patients, and they should be recommended in these patients, as the potential benefits widely outweigh the risk of SE. Treatment adjustment might be considered with the aim of minimising SE risk and flare.
- Published
- 2022
46. Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
- Author
-
Gatto, M, Radice, F, Saccon, F, Calatroni, M, Frontini, G, Trezzi, B, Zen, M, Ghirardello, A, Tamborini, F, Binda, V, L'Imperio, V, Doria, A, Vaglio, A, Sinico, R, Moroni, G, Iaccarino, L, Gatto, Mariele, Radice, Francesca, Saccon, Francesca, Calatroni, Marta, Frontini, Giulia, Trezzi, Barbara, Zen, Margherita, Ghirardello, Anna, Tamborini, Francesco, Binda, Valentina, L'Imperio, Vincenzo, Doria, Andrea, Vaglio, Augusto, Sinico, Renato Alberto, Moroni, Gabriella, Iaccarino, Luca, Gatto, M, Radice, F, Saccon, F, Calatroni, M, Frontini, G, Trezzi, B, Zen, M, Ghirardello, A, Tamborini, F, Binda, V, L'Imperio, V, Doria, A, Vaglio, A, Sinico, R, Moroni, G, Iaccarino, L, Gatto, Mariele, Radice, Francesca, Saccon, Francesca, Calatroni, Marta, Frontini, Giulia, Trezzi, Barbara, Zen, Margherita, Ghirardello, Anna, Tamborini, Francesco, Binda, Valentina, L'Imperio, Vincenzo, Doria, Andrea, Vaglio, Augusto, Sinico, Renato Alberto, Moroni, Gabriella, and Iaccarino, Luca
- Abstract
Objective To investigate second kidney biopsy as predictor of end-stage kidney disease (ESKD) in active lupus nephritis (LN). Methods Patients with biopsy-proven LN (International Society of Nephrology/Renal Pathology Society 2003) who had undergone a second kidney biopsy between January 1990 and December 2018 were included. Clinical and histological findings at first and at second biopsy were analysed with Cox proportional hazard models to predict ESKD, defined as start of kidney replacement therapy. Survival curves were calculated with Kaplan-Meier method. Results Ninety-two patients with LN were included, 87% females, mean follow-up 17.9±10.1 years. Reasons for second kidney biopsy encompassed nephritic flares (n=28, 30.4%), proteinuric flares (n=46, 50%) or lack of renal response (n=18, 19.5%). Class switch from first biopsy occurred in 50.5% of cases, mainly from non-proliferative towards proliferative classes. Class IV remained stable in over 50% of cases. Twenty-five patients (27.2%) developed ESKD, mostly belonging to the nephritic flare group (17/28, 60.7%). Independent predictors of ESKD at second biopsy were activity index (AI; (HR 95% CI) 1.20 (1.03 to 1.41), p=0.022), chronicity index (CI; 1.41 (1.09 to 1.82), p=0.008) and 24h-proteinuria (1.22 (1.04 to 1.42), p=0.013). AI≥2 (log-rank p=0.031), CI >4 (log-rank p=0.001) or proteinuria ≥3.5 g/day (log-rank=0.009) identified thresholds for higher ESKD risk. In a subgroup analysis, glomerular activity and tubular chronicity mostly accounted for AI and CI association with ESKD. No histological or laboratory predictors emerged at first biopsy (95% CI): AI: 0.88 to 1.19; CI: 0.66 to 1.20; proteinuria 0.85 to 1.08. Conclusions Findings at second but not at first kidney biopsy in patients with persistently active or relapsing LN inform about ESKD development in a long-term follow-up.
- Published
- 2022
47. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy
- Author
-
Moroni, Gabriella, Depetri, Federica, Del Vecchio, Lucia, Gallelli, Beniamina, Raffiotta, Francesca, Giglio, Elisa, Brunini, Francesca, DʼAmico, Marco, Longhi, Selena, Radice, Antonella, Messa, Piergiorgio, and Sinico, Renato Alberto
- Published
- 2017
- Full Text
- View/download PDF
48. Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood
- Author
-
Chinello, Clizia, primary, de Haan, Noortje, additional, Capitoli, Giulia, additional, Trezzi, Barbara, additional, Radice, Antonella, additional, Pagani, Lisa, additional, Criscuolo, Lucrezia, additional, Signorini, Stefano, additional, Galimberti, Stefania, additional, Sinico, Renato Alberto, additional, Wuhrer, Manfred, additional, and Magni, Fulvio, additional
- Published
- 2022
- Full Text
- View/download PDF
49. The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study
- Author
-
Gerosa, Maria, primary, Schioppo, Tommaso, additional, Argolini, Lorenza Maria, additional, Sciascia, Savino, additional, Ramirez, Giuseppe Alvise, additional, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Bonelli, Grazia, additional, Alberici, Federico, additional, Mescia, Federica, additional, Moroni, Luca, additional, Tamborini, Francesco, additional, Miraglia, Paolo, additional, Bellocchi, Chiara, additional, Beretta, Lorenzo, additional, Roccatello, Dario, additional, Dagna, Lorenzo, additional, Bozzolo, Enrica, additional, and Caporali, Roberto, additional
- Published
- 2022
- Full Text
- View/download PDF
50. Corrigendum to “Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis” [Kidney International Reports Volume 9, Issue 4, April 2024, Pages 1047–1056]
- Author
-
Gatto, Mariele, Frontini, Giulia, Calatroni, Marta, Reggiani, Francesco, Depascale, Roberto, Cruciani, Claudio, Quaglini, Silvana, Sacchi, Lucia, Trezzi, Barbara, Bonelli, Grazia Dea, L’Imperio, Vincenzo, Vaglio, Augusto, Furlan, Claudia, Zen, Margherita, Iaccarino, Luca, Sinico, Renato Alberto, Doria, Andrea, and Moroni, Gabriella
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.